Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) EBT Margin (2018 - 2025)

X4 Pharmaceuticals' EBT Margin history spans 6 years, with the latest figure at 931.66% for Q4 2025.

  • For Q4 2025, EBT Margin rose 182727.0% year-over-year to 931.66%; the TTM value through Dec 2025 reached 225.44%, up 122705.0%, while the annual FY2025 figure was 225.44%, 122705.0% up from the prior year.
  • EBT Margin reached 931.66% in Q4 2025 per XFOR's latest filing, up from 1690.93% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 16136.94% in Q2 2024 to a low of 6550.18% in Q3 2024.
  • Average EBT Margin over 4 years is 1203.93%, with a median of 1061.4% recorded in 2022.
  • The largest YoY upside for EBT Margin was 485924bps in 2025 against a maximum downside of -1743973bps in 2025.
  • A 4-year view of EBT Margin shows it stood at 2542.83% in 2022, then decreased by -15bps to 2165.55% in 2023, then plummeted by -227bps to 2758.93% in 2024, then surged by 66bps to 931.66% in 2025.
  • Per Business Quant, the three most recent readings for XFOR's EBT Margin are 931.66% (Q4 2025), 1690.93% (Q3 2025), and 1302.79% (Q2 2025).